Abstract
Objective Modeling of the ophthalmologist’s decision-making process for activity detection in neovascular age-related macular degeneration with a multi-task convolutional deep neuronal network which takes intra- and subretinal fluid into account.
Design A cohort study to evaluate the multi-task deep learning model for activity detection.
Participants n = 70 patients (46 female, 24 male) attended the University Eye Hospital Tübingen between 21.2.2018 and 27.6.2018. 3762 optical coherence tomography B-scans (right eye: 2011, left eye: 1751) were acquired from them with Heidelberg Spectralis, Heidelberg, Germany.
Methods B-scans were graded by a retina specialist and an ophthalmology resident, and then used to develop a multi-task deep learning model to concurrently predict disease activity in neovascular age-related macular degeneration along with the presence of sub- and intraretinal fluid.
Main outcome measures Performance metrics compared to single-task networks, visualization of the representation driving the DNN-based decisions using t-distributed stochastic neighbor embedding and analysis of the model’s decisions via clinically validated saliency mapping techniques.
Results The multi-task model surpassed single-task networks in accuracy for activity detection. Visualizations via t-distributed stochastic neighbor embedding and saliency maps highlighted that the network’s decisions for activity of neovascular age-related macular degeneration were based on the presence of sub- and intraretinal fluids, the optical coherence tomography characteristics used for treatment decision in clinical routine.
Conclusion Multi-task learning increases the performance of neuronal networks for predicting disease activity, while providing clinicians with an easily accessible decision control, which resembles human reasoning.
Competing Interest Statement
PB holds shares of eye2you GmbH. MSA, HF, LK, WI, GA and FZ declare no competing interest.
Funding Statement
Financial support was provided by German Ministry of Science and Education (BMBF) through the Tuebingen AI Center (FKZ 01IS18039A) and the German Science Foundation for funding through a Heisenberg Professorship (BE5601/4-2) and the Excellence Cluster "Machine Learning -- New Perspectives for Science" (EXC 2064, project number 390727645), Junior Clinician Scientist Program of the Faculty of Medicine, Eberhard Karls University of Tuebingen, Germany (application number 463-0-0) and the Novartis AG. The sponsor or funding organization had no role in the design or conduct of this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the local institutional ethics committee of the University of Tuebingen. Due to the retrospective character of the study, the requirement for patient consent was waived by the ethics committee. The study was conducted in accordance with the tenets of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Meeting Presentation: The manuscript is under consideration for presentation at the 120. Congress of the DOG (Deutsche Ophthalmologische Gesellschaft), 29.09.–02.10.2022, Berlin, Germany
Financial support: Financial support was provided by German Ministry of Science and Education (BMBF) through the Tübingen AI Center (FKZ 01IS18039A) and the German Science Foundation for funding through a Heisenberg Professorship (BE5601/4-2) and the Excellence Cluster “Machine Learning — New Perspectives for Science” (EXC 2064, project number 390727645), Junior Clinician Scientist Program of the Faculty of Medicine, Eberhard Karls University of Tübingen, Germany (application number 463–0–0) and the Novartis AG. The sponsor or funding organization had no role in the design or conduct of this research.
Conflict of Interest: PB holds shares of eye2you GmbH. MSA, HF, LK, WI, GA and FZ declare no competing
Address for preprints: Prof. Dr. rer. nat. P. Berens, Werner Reichardt Centre for Integrative Neuroscience (CIN) Institute for Ophthalmic Research, University of Tübingen, Otfried-Müller-Str. 25, D-72076 Tübingen, Germany. Phone: +49 (0)7071 29-88833, philipp.berens{at}uni-tuebingen.de
1 keras.applications.inception_v3.preprocess_input
Data Availability
The optical coherence tomography scans were obtained from the University Eye Clinic and their use was permitted by the Institutional Ethics Committee of the University of Tuebingen.
